Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Homburg, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homburg, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 17, No. 4, 853-856, April 2002
© 2002 European Society of Human Reproduction and Embryology

Should patients with polycystic ovarian syndrome be treated with metformin?

A note of cautious optimism

Roy Homburg

Lis Maternity Hospital, Tel Aviv (Sourasky) Medical Centre, Tel Aviv 64239, Israel (affiliated to the Sackler School of Medicine, Tel Aviv University). E-mail: homburg{at}netvision.net.il

Hyperinsulinaemia has proved to be a key link in the enigmatic generation of the symptoms of polycystic ovarian syndrome (PCOS), i.e. anovulatory infertility and the skin stigmata induced by hyperandrogenism. Regression of these symptoms may be achieved by reducing the hyperinsulinaemia. As obesity exaggerates the expression of the symptoms induced by hyperinsulinaemia, a low calorie diet and lifestyle change resulting in loss of weight for obese women with PCOS is capable of reversing these symptoms. Insulin-sensitizing agents, predominately metformin, have been examined for their ability, in all patients with PCOS, to achieve similar beneficial changes to those induced by loss of weight in the obese. While the scientific value of many of these studies is questionable and solid evidence of efficiency and safety is not complete, the honourable intent of lowering high insulin levels in this way prompts the bottom line of this debate to strike a note of cautious optimism that insulin-sensitizing agents will be of some clinical usefulness both in the short-term aiding of infertility treatment and, possibly, in the prevention of the long-term sequelae for this troublesome and very prevalent condition.

Key words: hyperinsulinaemia/metformin/polycystic ovarian syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
M. F. Costello, B. Shrestha, J. Eden, N. P. Johnson, and P. Sjoblom
Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review
Hum. Reprod., May 1, 2007; 22(5): 1200 - 1209.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
G. Onalan, B. Selam, Y. Baran, M. Cincik, R. Onalan, U. Gunduz, A. U. Ural, and R. Pabuccu
Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF
Hum. Reprod., September 1, 2005; 20(9): 2391 - 2395.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. Homburg
Clomiphene citrate--end of an era? a mini-review
Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
D. Cibula, M. Fanta, J. Vrbikova, S. Stanicka, K. Dvorakova, M. Hill, J. Skrha, J. Zivny, and J. Skrenkova
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients
Hum. Reprod., January 1, 2005; 20(1): 180 - 184.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al.
Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J. M Lord, I. H K Flight, and R. J Norman
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
BMJ, October 25, 2003; 327(7421): 951.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. J. Glueck, A. Moreira, N. Goldenberg, L. Sieve, and P. Wang
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin
Hum. Reprod., August 1, 2003; 18(8): 1618 - 1625.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. A. Stadtmauer, B. C. Wong, and S. Oehninger
Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction
Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. E. Nestler
Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement
Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.